Trial Profile

A phase III study of Pelareorep in combination with Atezolizumab in early-stage breast cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 26 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Pelareorep (Primary)
Indications Early breast cancer
Focus Registrational; Therapeutic Use

Most Recent Events

26 Mar 2020 New trial record
24 Mar 2020 According to an Oncolytics Biotech media release, Cohorts 1 and 2 from AWARE-1 study, represent the target tumor type of HR+ / HER2- and data from these patients will inform the design of this planned phase 3.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com